Posts filtered by tags: Bourla[x]


 

The COVID vaccine was developed in record time thanks to mRNA. Pfizer's CEO says the technology should now be used on other viral diseases like the flu.

The Pfizer Covid-19 vaccine. Dado Ruvic/Reuters Dado Ruvic/Reuters Covid-19 vaccine forwarded vaccine science years, Pfizer's CEO said, and now it's time to use advances for other viral diseases, such as the flu. "We'll be able to provide medical solutions for other devastating diseases," the CEO said. The Pfizer BioNTech vaccine used a new method with messenger RNA to initiate the immune response. Moderna's vaccine also used mRNA. Visit Business Insider's homepage for more stories. The Co...
Tags: News, Trends, Healthcare, Fda, Pfizer, Vaccine, Flu Vaccine, Jpmorgan, Moderna, mRNA, Albert Bourla, Bourla, Burla, Ugur Sahin, Natasha Dailey, Reuters Dado Ruvic Reuters Covid


Why you're not fully protected from COVID-19 after a single vaccine dose

Both Pfizer and Moderna'a COVID-19 vaccines require two shots, given weeks apart. Siphiwe Sibeko/Pool via AP Most COVID-19 vaccines are given as two shots, administered several weeks apart.  Protection does not start when the needle hits your arm.  It takes some days after each shot for the body to mount its own immune response to the novel coronavirus and prevent disease. Experts don't know exactly how protected from infection people are after their first shot, but there are signs of ...
Tags: UK, Science, California, Cdc, Kentucky, US, Alabama, Trends, Georgia, Healthcare, Astrazeneca, Cbs, Fda, University of Pennsylvania, Pfizer, Oxford University


Pfizer CEO Albert Bourla yet to be vaccinated, says won't 'cut the line'

Pfizer Albert Bourla said that Pfizer runs a lot of polls to see what would make people willing to take the vaccine. Bourla added that...
Tags: Pfizer, Albert Bourla, Bourla, Pfizer Albert Bourla


Pfizer's CEO will wait to get a COVID-19 vaccine, and says company executives won't 'cut the line'

Pfizer's CEO Albert Bourla. Drew Angerer/Getty Images Pfizer executives, including its CEO Albert Bourla, won't "cut the line" to get a COVID-19 vaccine, Bourla told CNBC Monday. "I'm 59 years old, in good health, I'm not working on the frontline, so my type it is not recommended to get vaccination now," he told CNBC. But Bourla noted that polls conducted by Pfizer suggest that people would be more willing to take the vaccine if he, as the company's CEO, got the shot. "I'm trying to fi...
Tags: Cdc, White House, New York City, US, America, Trends, Bloomberg, Joe Biden, Healthcare, Fda, Pfizer, Biden, Donald Trump, George W Bush, Cnbc, Centers for Disease Control and Prevention CDC


Pfizer's CEO says skipping the second dose of its coronavirus vaccine would be 'a very big mistake,' despite data suggesting partial protection from a single shot

Pfizer CEO Albert Bourla AP Photo/Pablo Martinez Monsivais Getting only one dose of a leading coronavirus vaccine would be "a very big mistake," Pfizer CEO Albert Bourla said Tuesday.  Pfizer's coronavirus vaccine is given as two doses, spaced 21 days apart. The vaccine is 95% effective at preventing COVID-19 when people get two doses. New data released Tuesday suggested a single dose was about 52% effective at prevent COVID-19, in the time until people got their second shot. The UK began ...
Tags: UK, US, Trends, Fda, Pfizer, Polaroid, Pablo Martinez Monsivais, Moderna, Andrew Dunn, Albert Bourla, Bourla, Albert Bourla Pfizer


Pfizer's chairman says it's not clear whether people who are vaccinated can still spread COVID-19

Pfizer CEO Albert Bourla. AP Photo/Pablo Martinez Monsivais Pfizer's CEO said it's not clear if the company's coronavirus vaccine will no longer be able to spread the virus to other people. Albert Bourla told NBC's "Dateline": "I think this is something that needs to be examined. We are not certain about that right now with what we know." Independent researchers have already made it clear that the trials used to test the vaccine did not examine its effects on transmission. The US could app...
Tags: UK, Science, Nbc, US, Trends, News UK, Pfizer, Lester Holt, US Food and Drug Administration FDA, Andrew Dunn, BioNtech, Albert Bourla, Bourla, Coronavirus, COVID-19, COVID


Pfizer just asked the FDA to authorize its coronavirus vaccine, a critical step before it can be given to more people

The first patient enrolled in Pfizer's COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore receiving an injection. University of Maryland School of Medicine/AP Photo Pfizer and BioNTech requested that the US Food and Drug Administration review their coronavirus vaccine for emergency authorization, they announced Friday. The vaccine was found to be 95% effective at preventing COVID-19 in a late-stage trial. The FDA has said it might ...
Tags: News, US, Trends, Healthcare, Fda, Pfizer, Baltimore, Centers For Disease Control And Prevention, Reuters, US Food and Drug Administration, Baylor College of Medicine, University of Maryland School of Medicine, Moderna, Andrew Dunn, BioNtech, Albert Bourla


Pfizer's CEO cashed out $5.6 million of stock after trumpeting its COVID-19 vaccine. That's 30% of his total compensation last year

A bank employee counts US dollar notes in this file photo from May 16, 2016. Kham/Reuters Pfizer CEO Albert Bourla raked in more than three times his base salary when he sold about 60% of his stock on Monday, shortly after trumpeting the stellar performance of his company's COVID-19 vaccine in a late-stage trial.The executive sold $5.6 million worth of shares due to "personal financial planning" and as part of a predetermined plan that he authorized in August, Pfizer told Reuters.Bourla's p...
Tags: US, Trends, Pfizer, Securities And Exchange Commission, Albert Bourla, Bourla, Alex Umansky, COVID, Theron Mohamed, Kham Reuters Pfizer, Reuters Bourla, Reuters An analysis of Bourla


Pfizer CEO made $5.6 million stock sale on same day as COVID-19 vaccine update: filing

Bourla authorized the sale of the shares on Aug. 19, provided the stock was at least at a certain price, as part of a predetermined...
Tags: Pfizer, Bourla


Pfizer's CEO cashed out 60% of his stock on the same day the company unveiled the results of its COVID-19 vaccine trial

Pfizer CEO Albert Bourla. AP Photo/Pablo Martinez Monsivais Pfizer chief executive Albert Bourla sold 62% of his stock in the company on the same day the drugmaker announced the results of its COVID-19 vaccine trial.Bourla sold $5.6 million in stock on Monday as part of a predetermined trading plan adopted on August 19.His stock sale was carried out at $41.94 a share. The 52-week-high for Pfizer stock is $41.99, which means the CEO cashed out his shares close to their highest this year.Pfiz...
Tags: Trends, Markets, Vaccination, Pfizer, Securities And Exchange Commission, Stock Options, US Food and Drug Administration, BioNtech, Albert Bourla, Bourla, Stock Sale, Coronavirus, COVID-19, Covid-19 Vaccine, Covid And Stocks, Vaccine News


Donald Trump and his son Donald Trump Jr., without evidence, accuse Pfizer of deliberately waiting until after Election Day to release its COVID-19 vaccine trial results

Samuel Corum/Getty Images, Tasos Katopodis/Getty Images President Donald Trump and his son Donald Trump Jr. on Monday baselessly accused Pfizer of deliberately waiting until after the US election to announce the promising early results of its COVID-19 vaccine trials. Pfizer CEO Albert Bourla on Monday told CNN that Pfizer had simply released the results "when the science told us the data was available." Though the announcement came Monday from Pfizer, and not a government organization, Tr...
Tags: Politics, Science, White House, US, Trends, Joe Biden, Cnn, Healthcare, Fda, Pfizer, Donald Trump, Trump, Mike Pence, Donald J Trump, US Food and Drug Administration, Donald Trump Jr


Donald Trump and Trump Jr. spread a conspiracy theory that Pfizer deliberately waited until after Election Day to release its COVID-19 vaccine trial results

Samuel Corum/Getty Images, Tasos Katopodis/Getty Images President Donald Trump and his son Donald Trump Jr. on Monday accused Pfizer of deliberately waiting until after the election to announce the promising early results of its COVID-19 vaccine trials. Trump said that both the US Food and Drug Administration and the Democrats "didn't want to have me get a Vaccine WIN, prior to the election, so instead it came out five days later." Trump Jr. suggested the timing of Pfizer's results, which...
Tags: Politics, Science, White House, US, Trends, Joe Biden, Cnn, Daily Mail, Healthcare, Fda, Pfizer, Donald Trump, Trump, Mike Pence, Donald J Trump, US Food and Drug Administration


LA County may tap schools as COVID vaccine sites

By ELIZABETH MARCELLINO | City News Service LOS ANGELES — As the possibility of a vaccine for COVID-19 takes shape, the Los Angeles County Board of Supervisors voted Tuesday to look at using schools as a key resource in rolling out vaccinations. Supervisor Janice Hahn recommended that the Department of Public Health work with school districts to evaluate the feasibility of setting up mass vaccination sites at local schools. “We’re going to be faced with one of the largest vaccination efforts eve...
Tags: News, California, California News, Los Angeles, Sport, Cnn, Soccer, New York Times, Vaccinations, Pfizer, Lausd, Local News, Anthony Fauci, Valencia, County, Los Angeles County


Trump and Pence celebrate Pfizer's COVID-19 vaccine success, but the government didn't fund its development

President Donald Trump delivers remarks on Operation Warp Speed. Shealah Craighead, White House On Monday, President Donald Trump and Vice President Mike Pence celebrated a milestone in the development of a coronavirus vaccine, but misleadingly presented Pfizer's milestone as an accomplishment of the Trump administration.  "HUGE NEWS: Thanks to the public-private partnership forged by President @realDonaldTrump, @pfizer announced its Coronavirus Vaccine trial is EFFECTIVE, preventing infec...
Tags: Politics, Science, White House, US, Trends, Joe Biden, Healthcare, Food And Drug Administration, Pfizer, The New York Times, Vaccine, Biden, Donald Trump, Trump, Health And Human Services, Mike Pence


Pfizer's head of vaccine development notes 'we have never taken any money from the U.S. government'

Pfizer distanced itself from the Trump administration's Operation Warp Speed on Monday after announcing some great news about its vaccine candidate.Pfizer on Monday revealed that a first interim analysis suggested its COVID-19 vaccine is more than 90 percent effective, and Vice President Mike Pence said this was "thanks to the public-private partnership forged" by President Trump. But The New York Times reports that Dr. Kathrin Jansen, Pfizer's head of vaccine research and development, "...
Tags: News, White House, Bloomberg, New York Times, Pfizer, Times, Donald Trump, Trump, Mike Pence, Jansen, Albert Bourla, Bourla, Operation Warp Speed, Kathrin Jansen Pfizer, Warp Speed


We won't get coronavirus vaccine results in October

Hollis Johnson/Business Insider Hello, Today in healthcare news: The door has closed on getting vaccine data in October, and Eli Lilly ends its antibody trial in hospitalized COVID-19 patients — while the US is paying $375 million for 300,000 vials of the investigational drug.Plus: A timeline of Trump's coronavirus statements matched with new cases over the course of the pandemic.  Pfizer CEO Albert Bourla AP Photo/Pablo Martinez Monsivais Pfizer's CEO repeatedly talked up getting ...
Tags: New York, US, Trends, Yale, Healthcare, Pfizer, Vaccine, Donald Trump, Anthony Fauci, Trump, Reuters, Lilly, Eli Lilly, Eli Lilly and Co, Andrew Dunn, Teladoc


Pfizer's CEO repeatedly talked up getting coronavirus vaccine data in October. Now, he's asking for patience.

Pfizer CEO Albert Bourla AP Photo/Pablo Martinez Monsivais Pfizer CEO Albert Bourla effectively closed the door Tuesday on knowing whether or not its experimental coronavirus vaccine would work by the end of October.  On the New York pharma giant's third quarter earnings call, Bourla acknowledged the company has not yet started the first interim analysis for this final study, called a phase-three trial. Additionally, the CEO said it typically takes five to seven days for an independent boa...
Tags: Health, New York, Science, Trends, Healthcare, Cbs, Fda, Pfizer, Biotech, Donald Trump, Anthony Fauci, US Food and Drug Administration, Pharmaceutical, Moderna, Andrew Dunn, Moncef Slaoui


Pfizer Announcement All But Ends Worries About Pre-Election Day Vaccine Campaign Prop

Pfizer said that it would likely seek emergency approval for a COVID-19 vaccine in late November, citing recent federal guidance that toughened approval standards for a vaccine, despite President Trump’s efforts to push for a shot by the “special day” of Nov. 3. In an open letter released Friday, Pfizer CEO and Chairman Albert Bourla said that “assuming positive data, Pfizer will apply for Emergency Authorization Use in the U.S. soon after the safety milestone is achieved in the third week of...
Tags: UK, News, Senate, Food And Drug Administration, Astrazeneca, Fda, Pfizer, Vaccine, Trump, Vanderbilt University, HHS, TPM, William Schaffner, Moderna, Schaffner, Muckraker


Moderna CEO says the global population could start getting access to its vaccine by late March or early April 2021

Moderna CEO Stephane Bancel at the 2019 Forbes Healthcare Summit in New York City in December 2019. Steven Ferdman/Getty Images The CEO of Moderna said Wednesday that he expects its coronavirus vaccine to be ready for use in late March or early April 2021. "I think a late Q1, early Q2 approval is a reasonable timeline," Stéphane Bancel told a conference hosted by the Financial Times. Bancel added that Moderna would be ready to submit the vaccine to the US Food and Drug Administration for "...
Tags: Politics, New York City, US, Trends, Healthcare, News UK, Fda, Associated Press, Pfizer, Vaccine, Donald Trump, Cnbc, Trump, US Food and Drug Administration, US Food and Drug Administration FDA, EUA


Pfizer, Last Hope For Pre-Election COVID Vaccine, Hits Out At ‘Politicization’ During Debate

Pfizer’s CEO warned against a COVID-19 vaccine being politicized in a letter to employees obtained by CNBC, after a Tuesday Presidential debate in which President Trump repeated his promise of a pre-election vaccine. Pfizer CEO Albert Bourla said that he was “disappointed that the prevention for a deadly disease was discussed in political terms rather than scientific facts.” Out of the three COVID-19 vaccine candidates farthest along in testing, Pfizer’s is the only one with a chance at pre-e...
Tags: News, Astrazeneca, Fda, Pfizer, Vaccine, Cnbc, Trump, The Food and Drug Administration, Moderna, Muckraker, Albert Bourla, Bourla, Josh Kovensky, COVID-19, COVID


A Real Vaccine Before the Election? It’d Take a Miracle.

This story first appeared at ProPublica. ProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter to receive stories like this one in your inbox. Despite President Donald Trump’s promises of a vaccine next month and pundits’ speculation about how an “October surprise” could upend the presidential campaign, any potential vaccine would have to clear a slew of scientific and bureaucratic hurdles in record time. In short, it would take a miracle. We talke...
Tags: New York, News, White House, Boston, Food And Drug Administration, Astrazeneca, Cbs, National Institutes of Health, Philadelphia, Fda, University of Pennsylvania, Pfizer, Donald Trump, Us Department Of Defense, Trump, Jpmorgan


Pfizer CEO: Company refused taxpayer money for COVID-19 vaccine development to 'liberate our scientists'

Pfizer chose not to take U.S. taxpayer money to help fund its coronavirus vaccine development, a move that CBS News' Margaret Brennan pointed out on Sunday is a bit of a financial risk for the pharmaceutical giant.CEO Albert Bourla admitted that it will indeed "be painful" if the vaccine fails, but "at the end of the day it's only money" and the lack of taxpayer funds won't "break our company." It was more important for Bourla that his scientists were able to work without any strings...
Tags: News, Stephen Colbert, Cbs News, Food And Drug Administration, Pfizer, Chris Evans, Trump, Flynn, Barr, Margaret Brennan, Albert Bourla, Bourla, COVID


White House faces skepticism over COVID vaccine

By LINDA A. JOHNSON and MICHELLE R. SMITH | Associated Press Could the U.S. really see a coronavirus vaccine before Election Day? A letter from federal health officials instructing states to be ready to begin distributing a vaccine by Nov. 1 — two days before the election — has been met, not with exhilaration, but with suspicion among some public health experts, who wonder whether the Trump administration is hyping the possibility or intends to rush approval for political gain. The skepticism co...
Tags: Politics, News, Vladimir Putin, California, Cdc, Senate, White House, Sport, Cnn, Soccer, Food And Drug Administration, Cbs, Fda, Npr, Pfizer, Johnson


Pfizer CEO says could be seeking regulatory approval for vaccine in October, possible to have 100 mil doses this year

The Washington Post interviewed Pfizer CEO Albert Bourla about a Covid-19 vaccine that could be ready this year: In a Washington Post Live interview, Pfizer CEO Albert Bourla, DVM, PhD said the company could seek regulatory approval for their coronavirus vaccine as soon as October. Bourla said patients’ progress would be tracked for over two years. According to Bourla, the company could have approximately 100 million doses this year, which Americans would receive from the government for free....
Tags: Post, News, Washington Post, United States, Fda, Pfizer, Vaccines, Trump, Pandemic, Albert Bourla, Bourla, COVID-19, Washington Post Live, October Bourla


Pfizer CEO Bourla plans to testify at Senate drug pricing hearing

U.S. drugmaker Pfizer Inc said on Wednesday that its Chief Executive Albert Bourla plans to testify later this month at a Senate hearing examining rising prescription drug prices.
Tags: Money, Senate, businessNews, Pfizer, Pfizer Inc, Albert Bourla, Bourla


Pfizer to replace longtime CEO Read with veteran Bourla

Pfizer Inc Chief Executive Officer Ian Read will hand over the reins of the largest U.S. drugmaker to veteran insider Albert Bourla in January, after eight years at the helm, in the backdrop of increased scrutiny over drug pricing.
Tags: Money, businessNews, Pfizer, Pfizer Inc, Ian Read, Albert Bourla, Bourla


Pfizer replaces long-time CEO Read with veteran Bourla

Pfizer Inc said on Monday Chief Executive Ian Read would become executive chairman from the start of next year, handing the reins of the largest U.S. drugmaker to veteran insider Albert Bourla after eight years in charge.
Tags: Money, businessNews, Pfizer, Pfizer Inc, Ian Read, Albert Bourla, Bourla


Drugmaker Pfizer's CEO Read to leave in January

The drugmaker Pfizer will replace CEO Ian Read with Chief Operating Officer Albert Bourla in January.Pfizer said Monday that Read will then become executive chairman of the company's board of directors.The 56-year-old Bourla just... [Author: [email protected]]
Tags: Business, Pfizer, Ian Read, Albert Bourla, Bourla